PTC Therapeutics filings document a Delaware biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under PTCT. Its Form 8-K reports cover quarterly and annual financial results, Regulation FD disclosures, product and pipeline updates, FDA-related communications, and board or compensation matters.
Proxy materials describe annual meeting governance, director elections, executive compensation, equity awards and related shareholder matters. The filing record also includes disclosures tied to rare-disease programs such as Sephience™ (sepiapterin), votoplam and Translarna™ (ataluren), along with the company’s capital structure and public-company reporting obligations.
PTC Therapeutics, Inc. chief executive officer Matthew B. Klein reported a mix of equity compensation and related tax sales. On May 13, 2026, he acquired 12,500 shares of common stock through earned performance-based RSUs after a pre-established milestone was certified.
Of these earned RSUs, 6,250 shares vested immediately on May 13, 2026 and another 6,250 shares are scheduled to vest on May 13, 2027. On May 14, 2026, a total of 12,572 shares of common stock were sold in open-market transactions solely to satisfy tax withholding obligations under an irrevocable sell-to-cover election. Following these transactions, Klein directly owned 393,998 shares of PTC Therapeutics common stock.
PTC Therapeutics ownership update: The Toronto-Dominion Bank reports beneficial ownership of 3,025,945 shares of common stock, representing 3.7% of the class. The filing is an Amendment No. 1 to a Schedule 13G/A and is signed on 05/15/2026.
The statement lists sole voting and sole dispositive power over the same 3,025,945 shares. The filing notes ownership is 5% or less of the class.
Janus Henderson Group plc reports beneficial ownership of 7,193,433 shares of PTC Therapeutics, Inc. as of 03/31/2026 This represents 8.7% of the company's common stock. The filing states the Asset Managers exercise shared voting and shared dispositive power over these shares and disclaim rights to receive dividends or sale proceeds on behalf of the managed accounts. The report clarifies the holdings are held across multiple Janus Henderson asset management entities acting for client-managed portfolios.
Filer submitted a Form 144 notifying the sale of Common stock. The notice lists 2,812 shares identified for sale on 05/15/2026 and shows prior reported sales by Mark Boulding of 2,265 shares on 04/06/2026 and 3,540 shares on 05/08/2026. The filing records cash settlement methods.
PTCT reported Form 144 transactions showing sales of Common stock by Matthew Klein and a restricted stock vesting. The filing lists three sales by Matthew Klein: 7,371 shares on 02/18/2026 for $511,227.50, 2,662 shares on 03/12/2026 for $170,572.44, and 2,850 shares on 04/21/2026 for $202,171.31. The excerpt also shows 2,572 shares vested as restricted stock on 05/13/2026 reported as compensation.
PTCT Rule 144 notice reporting proposed and recent transactions in Common Stock. The filing shows two restricted stock vesting events of 4,384 shares on 12/01/2025 and 5,616 shares on 12/29/2025. It also discloses three market sales by Matthew Klein during the prior three months: 7,371 shares for $511,227.50 on 02/18/2026, 2,662 shares for $170,572.44 on 03/12/2026, and 2,850 shares for $202,171.31 on 04/21/2026.
PTC Therapeutics executive Mark Elliott Boulding reported an exercise-and-sale transaction in company stock. On May 8, 2026, he exercised stock options to acquire a total of 3,540 shares of common stock at an exercise price of $46.54 per share.
That same day, he executed open-market sales totaling 3,540 shares at prices ranging from approximately $78.00 to $79.31 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on September 10, 2025. Following these transactions, he directly holds 105,212 shares of PTC Therapeutics common stock.
PTCT affiliate submitted a Form 144 notice to sell 3,540 shares of Common Stock. The filing lists an option granted on 01/03/2025 and a planned sale date of 05/08/2026. The filing also shows three recent dispositions by Mark Boulding totaling 8,097 shares sold on 02/17/2026, 02/19/2026, and 04/06/2026, and reports 82,949,338 shares outstanding as of 05/08/2026.
PTC Therapeutics reports Q1 2026 results showing solid product growth but a small loss. Total revenues were $272.6 million, down from $1.18 billion a year earlier when a large Novartis upfront payment boosted collaboration revenue. Net product revenue grew to $225.6 million, led by Sephience for PKU and DMD therapies Translarna and Emflaza, while royalty revenue from Evrysdi and other partnered products reached $46.8 million. The quarter showed an operating profit of $45.0 million, but after $49.0 million of net interest expense, mainly from the royalty financing and convertible notes, PTC recorded a net loss of $2.8 million. Cash, cash equivalents and marketable securities totaled about $1.89 billion, and management believes this, together with product sales and Novartis milestones, will fund operations for at least twelve months. The filing also highlights progress across rare‑disease programs, including global launches of Sephience, the Phase 3 votoplam program for Huntington’s disease now led by Novartis, and ongoing regulatory work on vatiquinone for Friedreich’s ataxia.
PTC Therapeutics, Inc. reported first quarter 2026 total revenue of $272.6 million, including $225.6 million in net product revenue and $46.8 million in royalty revenue. Management said this strong start supports raising full-year 2026 product revenue guidance.
Global Sephience sepiapterin revenue reached $125 million in the quarter, reflecting 36% quarter-over-quarter growth. The company reported a small net loss of $2.8 million, or $(0.03) per basic and diluted share, compared with a large prior-year profit that included substantial collaboration revenue.
PTC highlighted positive topline results from a 24‑month interim analysis of the PIVOT‑HD votoplam extension study and continued work on the global Phase 3 INVEST‑HD study. An open-label vatiquinone registration study is planned to start in Q3 2026. Cash, cash equivalents and marketable securities were $1.89 billion as of March 31, 2026.